Resultado de búsqueda
Hace 15 horas · Succession planning has evolved significantly in recent years. It’s no longer just about grooming internal talent for leadership roles. In today’s dynamic business environment, a more holistic ...
Hace 1 hora · Xeris Biopharma Holdings (NASDAQ:XERS) announced a CEO succession plan with John Shannon taking over from Paul Edick on August 1, 2024. Edick, the current CEO and chairman, will retire from his roles after more than seven years with the company. Shannon, currently Xeris’ president and COO, will succeed Edick as CEO and join the Board of ...
Hace 15 horas · Pursuant to the Company’s succession plan, the Board has appointed, John P. Shannon, Xeris’ President and Chief Operating Officer, as the new CEO and a member of the Board of Directors. Mr.
Hace 15 horas · Xeris Biopharma Holdings (NASDAQ:XERS) announced a CEO succession plan with John Shannon taking over from Paul Edick on August 1, 2024. Edick, the current CEO and chairman, will retire from his ...
Hace 15 horas · Pursuant to the Company’s succession plan, the Board has appointed, John P. Shannon, Xeris’ President and Chief Operating Officer, as the new CEO and a member of the Board of Directors.
Hace 15 horas · Xeris Biopharma has announced a CEO succession plan effective August 1, 2024. John Shannon, the company's current President and COO, will succeed Paul Edick as CEO and join the Board of Directors. Edick will continue in a senior advisory role until February 1, 2026. Marla S. Persky will become the new Chairperson of the Board.
Hace 15 horas · Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced a CEO succession plan effective August 1, 2024, under which Paul R. Edick will be retiring from his day-to-day operational and Chairman role at Xeris after more than ...
